In This Article:
Whilst it may not be a huge deal, we thought it was good to see that the NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Chief Financial Officer, Ronald McClurg, recently bought US$100k worth of stock, for US$0.50 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.
NeuroOne Medical Technologies Insider Transactions Over The Last Year
In fact, the recent purchase by Ronald McClurg was the biggest purchase of NeuroOne Medical Technologies shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at above the current price of US$0.43. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
Over the last year, we can see that insiders have bought 300.00k shares worth US$150k. But insiders sold 27.99k shares worth US$25k. Overall, NeuroOne Medical Technologies insiders were net buyers during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Check out our latest analysis for NeuroOne Medical Technologies
NeuroOne Medical Technologies is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
Does NeuroOne Medical Technologies Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 7.7% of NeuroOne Medical Technologies shares, worth about US$1.6m, according to our data. We do generally prefer see higher levels of insider ownership.
What Might The Insider Transactions At NeuroOne Medical Technologies Tell Us?
It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that NeuroOne Medical Technologies insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing NeuroOne Medical Technologies. To help with this, we've discovered 3 warning signs (1 can't be ignored!) that you ought to be aware of before buying any shares in NeuroOne Medical Technologies.